EMEA restructures

December 11, 2009
Angie Drakulich

Angie Drakulich was editorial director of Pharmaceutical Technology.

Pharmaceutical Technology Europe

The EMEA unveiled several changes to the organization, including a new structure and visual identity.

The EMEA has unveiled several changes to the organization, including a new structure and visual identity.

One primary structural change involves integrating human pre- and post-authorization activities into one unit, “to guarantee seamless lifecycle-management of medicines,” according to a press statement. Also, a group will be dedicated to the management of product data and documentation to help improve the efficiency of data-management processes throughout the agency.

This is the second time the EMEA has undergone restructuring. Established in 1995, the agency’s “responsibilities and tasks have grown, giving it a stronger role in the protection of public and animal health in Europe,” according to the press statement. “All of this has been underpinned by the creation of additional scientific committees and advisory groups, which bring with them the need for enhanced coordination and support. Legislative proposals currently being considered by the European Parliament and Council are expected to bring further responsibilities to the Agency.”

As part of the agency’s new visual, or public, identity, the EMEA will launch a new website in the coming months. The site is expected to be easier for the public to use and designed to meet readers’ needs.

Going forth, the agency will now be known as the EMA as opposed to the EMEA.

www.emea.europa.eu